Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 9/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7071416 | 1.00 | GAA (0.52) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL4152753 | 0.87 | GAA (0.54) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL20581801 | 0.87 | GAA (0.54) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL15199916 | 0.85 | GAA (0.60) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL8197462 | 0.85 | GAA (0.60) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL2327582 | 0.85 | GAA (0.60) | GAANAAANFKB1NFKB2RELA | |
| SCHEMBL2975714 | 0.82 | GAA (0.57) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL318672 | 0.82 | GAA (0.57) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL2463048 | 0.82 | GAA (0.57) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL320341 | 0.82 | GAA (0.57) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275025-A1 | Substituted Lactams and Their Use as Anti-Cancer Agents | NOVARTIS AG | 2008-11-06 | — | — | US | disclosed |
| US-7378410-B2 | Substituted lactams and their use as anti-cancer agents | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-20060281731-A1 | Substituted lactams and their use as anti-cancer agents | BAIR, KENNETH WALTER | 2006-12-14 | — | — | US | disclosed |
| EP-1651633-A1 | SUBSTITUTED LACTAMS AND THEIR USE AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014574-A1 | SUBSTITUTED LACTAMS AND THEIR USE AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-6599898-B2 | Selected from the group consisting of breast, lung, non-small cell lung, osteolytic, colon and prostate | NOVARTIS AG (CH) | 2003-07-29 | — | — | US | disclosed |
| US-20030055041-A1 | Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors | KINDER FREDERICK RAY (US) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281731-A1 | Substituted lactams and their use as anti-cancer agents | TOP1, TOP2A, TOP2B | GAA 1376/4885NAAA 1434/4885NFKB1 651/4885 |
| US-20080275025-A1 | Substituted Lactams and Their Use as Anti-Cancer Agents | TOP1, TOP2A, MYC | GAA 2011/4885NAAA 798/4885NFKB1 677/4885 |
| US-20030055041-A1 | Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors | VHL, CAPRIN1, CAPN9 | GAA 1874/4885NAAA 706/4885NFKB1 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.